A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 12, 2013, Pages

  Hamasaki, Yoshifumi ^a   Doi, Kent ^a   Maeda Mamiya, Rui ^a   Ogasawara, Emi ^a   Katagiri, Daisuke ^a   Tanaka, Tamami ^a   Yamamoto, Tokunori ^b   Sugaya, Takeshi ^c   Nangaku, Masaomi ^a   Noiri, Eisei ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c Strategic and Regulatory Affairs Consulting Department   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

L FABP; PAI 1; Peritubular blood flow; Sarpogrelate; Tubulointerstitial fibrosis

Indexed keywords

CREATININE; FATTY ACID BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SARPOGRELATE; SEROTONIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MEGADOSE; FIBRIN DEPOSITION; HISTOPATHOLOGY; IN VITRO STUDY; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL TUBULOINTERSTITIAL FIBROSIS; SIGNAL TRANSDUCTION; UPREGULATION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

L-FABP; PAI-1; PERITUBULAR BLOOD FLOW; SARPOGRELATE; TUBULOINTERSTITIAL FIBROSIS;

ADENINE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; FIBROSIS; KIDNEY TUBULES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPHRITIS, INTERSTITIAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGIONAL BLOOD FLOW; SEROTONIN; SEROTONIN ANTAGONISTS; SUCCINATES; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84890336184     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00151.2013     Document Type: Article

References (60)

1. Ataka K, Maruyama H, Neichi T, Miyazaki J, Gejyo F. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 23: 315-323, 2003.
2. Chen CF, Yeh SU, Chien CT, Wu MS. Renal response during acute unilateral ureteral obstruction in rats. Neurourol Urodyn 20: 125-137, 2001.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007.
4. Doi K, Katagiri D, Negishi K, Hasegawa S, Hamasaki Y, Fujita T, Matsubara T, Ishii T, Yahagi N, Sugaya T, Noiri E. Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int 82: 1114-1120, 2012.
5. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17: 2999-3012, 2006.
6. Eto Y, Nitta K, Uchida K, Tsutsui T, Natori K, Kawashima A, Yumura W, Nihei H. Anti-mitogenic effects of sarpogrelate in cultured rat mesangial cells. Life Sci 60: PL193-PL199, 1997.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
8. Gonzalez J, Klein J, Chauhan SD, Neau E, Calise D, Nevoit C, Chaaya R, Miravete M, Delage C, Bascands JL, Schanstra JP, Buffin-Meyer B. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp Biol Med (Maywood) 234: 1511-1518, 2009.
9. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL. Serotonin 5-HT2A receptor induces TGF-fj1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am J Physiol Renal Physiol 276: F922-F930, 1999.
10. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 5: 203-211, 2009.
11. Hamasaki Y, Doi K, Okamoto K, Ijichi H, Seki G, Maeda-Mamiya R, Fujita T, Noiri E. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Lab Invest 92: 1161-1170, 2012.
12. Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 66: 484-488, 1991.
13. Iizuka K, Hamaue N, Machida T, Hirafuji M, Tsuji M. Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res 34: 18-30, 2009.
14. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143: 23-30, 2004.
15. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 165: 1243-1255, 2004.
16. Kanai H, Hiromura K, Kuroiwa T, Maezawa A, Yano S, Naruse T. Role of serotonin in nephrotoxic serum nephritis in WKY rats. J Lab Clin Med 129: 557-566, 1997.
17. Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, Matsuda H, Kobori S, Shichiri M. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 54: 1083-1092, 1998.
18. Kawano H, Tsuji H, Nishimura H, Kimura S, Yano S, Ukimura N, Kunieda Y, Yoshizumi M, Sugano T, Nakagawa K, Masuda H, Sawada S, Nakagawa M. Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97: 1697-1702, 2001.
19. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659-663, 2004.
20. Kim DC, Jun DW, Kwon YI, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS, Kim EK. 5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis. Liver Int 33: 535-543, 2013.
21. Kim W, Moon SO, Lee SY, Jang KY, Cho CH, Koh GY, Choi KS, Yoon KH, Sung MJ, Kim DH, Lee S, Kang KP, Park SK. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 17: 2474-2483, 2006.
22. Kobayashi S, Satoh M, Namikoshi T, Haruna Y, Fujimoto S, Arakawa S, Komai N, Tomita N, Sasaki T, Kashihara N. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with strep-tozotocin-induced diabetic nephropathy. Clin Exp Nephrol 12: 119-125, 2008.
23. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342: 1792-1801, 2000.
24. Liu RM. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 10: 303-319, 2008.
25. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 106: 1441-1443, 2000.
26. Mackensen-Haen S, Bader R, Grund KE, Bohle A. Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 15: 167-171, 1981.
27. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 83: 351-361, 1996.
28. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bum-garner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overex-pressing mice. Kidney Int 67: 2221-2238, 2005.
29. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the patho-genesis of renal fibrosis. Am J Physiol Renal Physiol 276: F39-F45, 1999.
30. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
31. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992.
32. Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int 73: 1374-1384, 2008.
33. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68: 228-236, 2005.
34. Nonogaki K, Nozue K, Oka Y. Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactiva-tion in obese Ay mice. Biochem Biophys Res Commun 351: 1078-1082, 2006.
35. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001.
36. Rasbach KA, Funk JA, Jayavelu T, Green PT, Schnellmann RG. 5-Hydroxytryptamine receptor stimulation of mitochondrial biogenesis. J Pharmacol Exp Ther 332: 632-639, 2010.
37. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006.
38. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
39. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2: 363-366, 1968.
40. Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardio-vasc Drug Rev 22: 27-54, 2004.
41. Santana AC, Degaspari S, Catanozi S, Delle H, de Sa Lima L, Silva C, Blanco P, Solez K, Scavone C, Noronha IL. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. Nephrol Dial Transplant 28: 1140-1149, 2013.
42. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003.
43. Seo JY, Park J, Yu MR, Kim YS, Ha H, Lee HB. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth fac-tor-beta1 during renal fibrosis in diabetes. Am J Nephrol 30: 481-490, 2009.
44. Sole MJ, Madapallimattam A, Baines AD. An active pathway for serotonin synthesis by renal proximal tubules. Kidney Int 29: 689-694, 1986.
45. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 21: 651-659, 2006.
46. Tamura M, Aizawa R, Hori M, Ozaki H. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. Histochem Cell Biol 131: 483-490, 2009.
47. Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, Fujita T, Noiri E. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 174: 1203-1211, 2009.
48. Tanaka T, Noiri E, Yamamoto T, Sugaya T, Negishi K, Maeda R, Nakamura K, Portilla D, Goto M, Fujita T. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol 108: e19-e26, 2008.
49. Trivedi H. Cost implications of caring for chronic kidney disease: are interventions cost-effective? Adv Chronic Kidney Dis 17: 265-270, 2010.
50. Uchida-Kitajima S, Yamauchi T, Takashina Y, Okada-Iwabu M, Iwabu M, Ueki K, Kadowaki T. 5-Hydroxytryptamine 2A receptor signaling cascade modulates adiponectin and plasminogen activator inhibitor 1 expression in adipose tissue. FEBS Lett 582: 3037-3044, 2008.
51. Ullmer C, Schmuck K, Kalkman HO, Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 370: 215-221, 1995.
52. Verbeke M, Van de Voorde J, de Ridder L, Lameire N. Beneficial effect of serotonin 5-HT2-receptor antagonism on renal blood flow auto-regulation in cyclosporin-treated rats. J Am Soc Nephrol 10: 28-34, 1999.
53. Xu J, Yao B, Fan X, Langworthy MM, Zhang MZ, Harris RC. Characterization of a putative intrarenal serotonergic system. Am J Physiol Renal Physiol 293: F1468-F1475, 2007.
54. Yamakawa J, Takahashi T, Itoh T, Kusaka K, Kawaura K, Wang XQ, Kanda T. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 26: 2477-2478, 2003.
55. Yamamoto T, Kajiya F. Intravital videomicroscopy. Methods Mol Med 86: 119-128, 2003.
56. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Goto M, Shinozaki N, Ohshima S, Sugaya T. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 18: 2894-2902, 2007.
57. Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T, Kadomatsu K, Nishimura M, Muramatsu T, Saito H. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 99: 2455-2458, 2002.
58. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 174: 2096-2106, 2009.
59. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 44: 230-234, 1986.
60. Yuen PS, Dunn SR, Miyaji T, Yasuda H, Sharma K, Star RA. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 286: F1116-F1119, 2004.